Skip to main content
Premium Trial:

Request an Annual Quote

People In The News: Sep 10, 2010

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – San Francisco-based molecular diagnostics startup MLC Dx recently disclosed in a filing with the US Securities and Exchange Commission several company executives.

Thomas Willis is the company's president and CEO. Prior to that, he worked at Affymetrix, following the firm's acquisition of ParAllele BioScience, a company he co-founded and where he served as CEO and later as chief scientific officer.

Malek Faham is the firm's CSO. Previously, he was vice president of oncology technology research at Affymetrix, and before that, director of research at ParAllele, which he also co-founded.

Genetic test startup Good Start Genetics has named Don Hardison its president and CEO. Hardison previously was chief operating officer of Laboratory Corporation of America and CEO of Exact Sciences.

He also serves as a director of Good Start, whose board will be chaired by Marc Beer, former CEO of ViaCell. The other directors are Robert Carpenter, director of Genzyme; Carl Gordon, general partner at OrbiMed; Gary Kurtzman, managing director at Safeguard Scientifics; and Lutz Giebel, managing partner at SV Life Sciences.

Caris Life Sciences has named Ian Walker to be VP of strategic marketing for Europe and Ian Abercrombie to serve as VP of commercial operations for Europe, both new positions.

Walker formerly was global director of molecular diagnostics at Novartis, where he helped start the firm's molecular diagnostics program, and he was worked at Astrazeneca as a brand and product manager. Abercrombie recently was European director of oncology for Genzyme Therapeutics, and before that he was a program director at Bioenvision, and he worked in management posts at two divisions of Johnson and Johnson.

DNA Genotek has tapped Patrick Walsh to be its chief financial officer. Walsh has spent 30 years in financial operations and management and 25 years at Nortel, where he was GM of the firm's ATM switching division.

ChanTest has named Thomas Oakley to be president and CEO, replacing Arthur Brown, who founded the company and is currently executive chairman and chief science officer.

Oakley recently was president and CEO of Bridge Pharmaceuticals, and he was founder and president of DTO Associates, a consulting firm focused on contract research and scientific firms. Oakley also spent more than nine years at Covance, where he was VP of finance and administration for the Early Development Group, VP and GM of the North American Chemistry Division, and global VP of business development.

Brown will continue with ChanTest and will focus on enhancing the firm's commercial pipeline and scientific capabilities.

XDx has appointed Matthew Meyer to take on the position of VP of corporate development and legal affairs. Meyer previously was VP of business development and general counsel at Cerimon Pharmaceuticals, and he has held senior management positions at Draeger Medical Systems and at Novartis Pharma and worked as an attorney for Pfizer.

Sequencing startup Stratos Genomics has disclosed the names of several of its officers, directors, and scientific advisors.

The company's co-founders are CEO Allan Stephan, chief scientific officer Mark Kokoris, and chief technology officer Bob McRuer.

Stephen Rose, managing director of Fisk Ventures, joins the company's board of directors in connection with a recent funding round. The other directors are Kokoris, McRuer, Harold Kawaguchi, Lee Huntsman, and Heiner Dreismann.

Stratos Genomics' science advisory board includes Larry Loeb, Robert Franza, Andre Marziali, Eugene Kolker, Patrick Stayton, Jay Shendure, and Buddy Ratner.

Former Life Technologies executive Ian Zhang has joined Neostem as president and managing director of its NeoStem China division. Previously, he was head of Asia Pacific integration at Life Technologies, where he served on the steering committee managing the acquisition and integration of Applied Biosystems. He also was the head of corporate development for Asia Pacific at Invitrogen.

Promoted? Changing jobs? GenomeWeb wants to know. E-mail [email protected] to appear in People In The News, a weekly roundup of industry comings and goings.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.